Introduction
============

In human assisted reproduction technologies (ARTs), *in vitro* maturation (IVM) of oocytes had emerged as an important field, especially when applied to women with a diagnosis of polycystic ovary syndrome ([@b1-mmr-16-02-1278],[@b2-mmr-16-02-1278]). However, embryos produced from IVM oocytes differ greatly from their *in vivo* counterparts in multiple aspects, including developmental competence and subsequent pregnancy rate ([@b3-mmr-16-02-1278]). A lack of the required maturation factors (growth factors and others) and proper hormonal milieu are likely to cause incomplete cytoplasmic maturation in IVM. Additionally, the procedure of IVM involves several steps, including the isolation, handling and culture of oocytes, which may exert more environmental stress on oocytes and early embryos compared with oocytes matured *in vivo*. Oxidative stress is one of the most harmful stress factors. *In vivo*, oocytes and embryos produce endogenous reactive oxygen species (ROS) that have an important role as second messengers in cellular functions through activation of cell signaling cascades ([@b4-mmr-16-02-1278]). However, excessive ROS can lead to serious consequences, including DNA fragmentation, enzymatic inactivation and cell death ([@b5-mmr-16-02-1278]). Progress in embryo developmental competence was obtained by optimizing culture mediums and IVM protocols. Supplementation of basic culture medium with serum and gonadotropins, amino acids, epidermal growth factor, vascular endothelial growth factor, cysteamine and other factors improved embryo developmental competence following *in vitro* fertilization (IVF)/intracytoplasmic sperm injection (ICSI) of oocytes matured *in vitro*.

N-acetyl-5-methoxytryptamine (melatonin), one of the most effective antioxidants, is a pleiotropic molecule with an important role in animal reproductive activities ([@b6-mmr-16-02-1278]) and reducing oxidative damage and may improve the survival environments of cells ([@b7-mmr-16-02-1278]). Melatonin is a derivative of tryptophan predominantly produced in the pineal gland of vertebrates and a potent free radical scavenger and antioxidant. Takasaki *et al* ([@b8-mmr-16-02-1278]) reported that oral melatonin can improve the quality of oocytes and may be useful as a new auxiliary drug for the treatment of infertility. When melatonin was added to semen extender or culture medium, sperm viability, oocyte competence and blastocyst development *in vitro* were significantly improved ([@b9-mmr-16-02-1278]). Kim *et al* ([@b10-mmr-16-02-1278]) reported that melatonin supplementation may be used to improve the clinical outcomes of typical IVM IVF-embryo transfer. Carr *et al* ([@b11-mmr-16-02-1278]) demonstrated the long-term safety of melatonin use. They reported open label follow-up data of 41 cases of the safety of melatonin use in 50 children. They concluded that there were no reported late-onset adverse effects.

The majority of the literature supports a protective/beneficial role for melatonin; however, some controversy remains. Li *et al* ([@b12-mmr-16-02-1278]) demonstrated that exogenous melatonin had no effect on development of cryopreserved metaphase II oocytes in mice.

To examine the potential beneficial effects of melatonin, immature oocytes from superovulation cycles were used in the present study, which was generally referred to as '*rescue* IVM'; these were used instead of immature oocytes from typical IVM cycles because this was a pilot study and this may also be applied on human oocytes. Different to immature oocytes in typical IVM cycles, the immature oocytes in '*rescue* IVM' were inhibited by the dominant follicle during development. Normally, these immature oocytes are considered to be of no value and are discarded. However, several studies have demonstrated their value ([@b13-mmr-16-02-1278],[@b14-mmr-16-02-1278]). In the current study, germinal vesicle (GV) or metaphase I stage (MI) oocytes were incubated with different concentrations of melatonin (10^−11^, 10^−9^, 10^−7^, 10^−5^ mol/l).

The advent of commercial microarrays and high-fidelity RNA amplification techniques have made it possible to profile gene expression in rarely available human oocytes and embryos to search for developmental regulators. In the current study, the transcriptomic profiles of the blastocysts developed from *in vivo* matured oocytes and *in vitro* matured oocytes with or without melatonin treatment were compared in an attempt to identify a molecular basis for the effect of melatonin on oocyte development.

Materials and methods
=====================

### Experimental patients and ethics

The current study was approved and reviewed by the Ethics Committee of Anhui Medical University (Hefei, China; approval no. 2015012). All patients in the study had provided informed consents for this research. A total of 200 women undergoing ICSI cycles at the Reproductive Medicine Center of the First Affiliated Hospital of Anhui Medical University (Hefei, China) were enrolled from December 2014 to September 2015. The enrolled patients met the following criteria: i) Patients were \<35 years old; ii) cycles were stimulated with standard long pituitary downregulation protocol as previously described ([@b15-mmr-16-02-1278]); iii) patients had undergone ICSI cycles; and iv) no chromosomal abnormalities. No significant differences were detected in sperm parameters and major clinical characteristics among the five groups that received varying MT concentrations ([Table I](#tI-mmr-16-02-1278){ref-type="table"}).

### Human oocyte collection and gamete manipulation

Controlled ovarian stimulation was achieved using a standard long pituitary downregulation protocol with gonadotropin-releasing hormone agonists and recombinant follicle stimulating hormone (FSH; Gonal-F; Merck KGaA, Darmstadt, Germany) for treatment of infertility. Follicular development was monitored by vaginal ultrasound. When at least three follicles reached 18 mm in diameter, 10,000 IU human chorionic gonadotropin (Livzon Pharmaceutical Co., Ltd., Shanghai, China) was administered. At \~36 h later, oocyte cumulus complexes (OCC) were collected under ultrasound guidance. The day prior to oocyte retrieval, serum was collected from each of the patients. The oocytes were from ICSI cycles and denuded so as to judge meiotic status as soon as possible. The immature oocytes at the GV or MI stage were donated for the research.

### Rescue IVM with or without melatonin treatment

The immature oocytes were placed in pre-equilibrated *in vitro* maturation (IVM) medium which was TCM-199 (Sigma-Aldrich; Merck KGaA) medium supplemented with 0.075 IU/ml human recombinant FSH, 0.1 mg/ml 17β-estradiol, 0.22 mM pyruvic acid, 0.6 g/l penicillin and streptomycin, 0.5 IU/ml human chorionic gonadotropin, 20% (v/v) patient serum with different concentrations of melatonin (0, 10^−11^, 10^−9^, 10^−7^,10^−5^ mol/l; Sigma-Aldrich; Merck KGaA) and incubated at 6% CO~2~, 5% O~2~ for \~24 h at 37°C. Oocytes with a visible polar body in the perivitelline space were regarded as matured. The ICSI procedure was carried out with fresh sperm from different samples. No significant differences were detected in sperm parameters, which included concentration and motility among the different groups.

The embryos developed to the blastocyst stage were vitrified on day 5. The quality of the blastocyst was assessed based on Gardner\'s grading system ([@b16-mmr-16-02-1278]).

### Blastocyst thawing for total RNA extraction, amplification, and quality measurement

Blastocysts developed from *in vivo* maturation oocytes, and *in vitro* maturation oocytes with (IVM-anti group) or without (IVM group) a certain concentration of melatonin treatment were thawed. Patients that had given birth to healthy babies donated surplus frozen blastocysts for the research, which were developed from *in vivo* maturation oocytes in ICSI cycles. The three groups of blastocysts, which had similar quality, were pooled in TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Total RNA was extracted from each group using the All-Prep DNA/RNA Micro kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. The purified RNA was then amplified in two rounds and digoxigenin-labeled according to the NanoAmp™ RT-IVT Labeling kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The quality and quantity of extracted and amplified RNA were measured using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). RNA integrity was assessed by standard denaturing agarose gel electrophoresis.

### RNA labeling and array hybridization

Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, Inc., Santa Clara, CA, USA). Briefly, total RNA from each group was linearly amplified and labeled with Cy3-UTP. The labeled cRNAs were purified by RNeasy Mini kit (Qiagen, Inc.). The concentration and specific activity of the labeled cRNAs (pmol Cy3/µg cRNA) were measured using the NanoDrop ND-1000. Each labeled cRNA (1 µg) was fragmented by adding 11 µl 10X blocking agent and 2.2 µl 25X fragmentation buffer, then heated at 60°C for 30 min, and lastly 55 µl 2X GE hybridization buffer was added to dilute the labeled cRNA from Agilent Gene Expression Hybridization kit (Agilent Technologies, Inc.). Hybridization solution (100 µl) was dispensed into the gasket slide and assembled to the gene expression microarray slide (cat no. G4845A; Agilent Technologies, Inc.). The slides were incubated for 17 h at 65°C in an Agilent Hybridization Oven. The slides were washed and the arrays were scanned by a G2565BA Agilent scanner. Three independent repetitions were performed, and a total of nine chips were used in this study.

### Microarray data analysis

Genes in three groups of blastocysts were compared in pairs. Agilent Feature Extraction software (version 11.0.1.1) was applied to analyze the acquired array images. Quantile normalization and subsequent data processing were performed with using the GeneSpring GX v12.1 software package (Agilent Technologies, Inc.). Following quantile normalization of the raw data, genes that at least three out of nine samples had flags in Detected ('All Targets Value') within the analysis software were selected for further analysis. Data were progressively filtered as follows: Measurements for each condition with 80% confidence were removed; less precise measurements based on control strength were removed; probes recorded as absent in all samples were removed and the measurements for probes representing the positive and fiducial controls were removed. Differentially expressed genes with statistical significance between the two groups were identified through fold change filtering (fold change ≥2.0; P≤0.05). Hierarchical clustering was performed using the R scripts ([@b17-mmr-16-02-1278]). Biological functional analysis of the differentially expressed genes was done using Gene Ontology (GO; [www.geneontology.gov](www.geneontology.gov)) and the Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.jp/kegg/pathway.html](www.genome.jp/kegg/pathway.html)) pathway database.

### Validation of important genes derived from microarray analyses by reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The levels of relevant mRNAs derived from microarray analyses including the products of certain important genes involved in a specific pathway, were determined by RT-qPCR using a One-Step SYBR PrimeScript RT-PCR kit (Takara Bio, Inc., Tokyo, Japan). The primers used in this study are presented in [Table II](#tII-mmr-16-02-1278){ref-type="table"}. Briefly, 2 mg total RNA was converted to cDNA according to the manufacturer\'s protocol. PCR was performed in a total reaction volume of 25 µl, including 10 µl SYBR Premix Ex Taq (2X), 0.5 µl ROX reference dye II (50X) ×3, 2 µl cDNA, 8 µl double-distilled water, 1 µl 10 mmol/l PCR forward and reverse primer. The RT-qPCR was set at an initial denaturation step of 10 min at 95°C, and 95°C (5 sec), 63°C (30 sec), and 72°C (30 sec) in a total of 40 cycles with a final extension step at 72°C for 5 min. RT-qPCR was used to quantify the mRNA levels of methionine adenosyltransferase 2A (MAT2A), catechol-O-methyltransferase (COMT), period circadian clock 1 (PER1), serine/threonine kinase 4 (STK4), cyclin G1 (CCNG1), interleukin 4 induced 1 (IL4I1), and forkhead box P3 (FOXP3) with GAPDH mRNA as the endogenous reference gene using the 2^−∆∆Cq^ method to perform the normalization ([@b18-mmr-16-02-1278]). Melting curve analysis was performed to confirm the quantitative PCR products. All experiments were carried out in three repetitions. Statistical comparisons were performed using the Student\'s t-test and the SPSS 16.0 statistical software (P≤0.05 was considered statistically significant).

### Statistical analysis

Data were expressed as the mean ± standard error, Statistical comparisons were performed using the Student\'s t test or a one-way analysis of variance followed by post-hoc Tukey\'s honest significant difference test and the SPSS 16.0 statistical software (SPSS, Inc., Chicago, IL, USA). P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics of the patients, effect of melatonin on maturation of human oocyte and embryo development

A total of 314 GV oocytes and 320 MI oocytes were collected from 200 patients younger than 35-years-old that had undergone ICSI cycle, and they were randomly distributed in the control group (no melatonin) and four other groups of varying MT concentrations. There was no significant difference in the ratio of GV/MI in each group. Maturation rate (no. of matured oocytes/total no. of oocytes), fertilization rate (no. of fertilized oocytes/no. of matured oocytes), cleavage rate (no. of cleaved oocytes/no. of fertilized oocytes), blastocyst rate (no. of blastocysts/no. of cleaved oocytes) and high quality blastocyst rate (no. of high quality blastocysts/no. of blastocysts) in the five groups are presented in [Table III](#tIII-mmr-16-02-1278){ref-type="table"}. The ratio of high quality blastocysts was significantly higher (P\<0.05) in 10^−5^ mol/l melatonin-treated group compared with the others groups. The fertilization rate, cleavage rate, and the blastocyst rate in 10^−5^ mol/l melatonin-treated group were also higher than others groups, but had no statistically significance. As for maturation rate, there were also no significant differences among these groups.

### Comparative gene expression for human blastocysts from oocytes matured in vitro and in vivo

For each group, \[IVM group, IVM-anti group (treated with 10^−5^ mol/l melatonin) and *in vivo* maturation\] 9 blastocysts matured from oocytes were thawed for total RNA extraction. For each group, 9 blastocysts were assigned to three PCR tubes filled with 400 µl TRIzol reagent on average, so as to be replicated three times. In order to clarify a gene prolife that may better reflect the differences between oocytes matured *in vivo* and *in vitro*, a cut-off of \>2-fold difference was applied. The three groups were compared pairwise. In blastocysts from the IVM group compared with the *in vivo* group, of 15,827 analyzed genes, 412 genes were identified as differentially expressed (P\<0.05), of which 180 were upregulated, and 232 genes were downregulated. For the IVM-anti group compared with the IVM group, of 15,827 analyzed genes, 821 genes were identified as differentially expressed (P\<0.05), of which 587 were upregulated, and 234 were downregulated. For the IVM-anti group compared with the *in vivo* group, of 15,827 analyzed genes, 1,312 genes are identified as differentially expressed (P\<0.05), of which 877 genes were upregulated, and 435 were downregulated. GenBank accession numbers, false discovery rate (FDR), regulation direction, biological processes and P-values of several representative differentially expressed genes are listed in [Table IV](#tIV-mmr-16-02-1278){ref-type="table"}. Supervised hierarchical clustering analysis was performed based on the data of differentially expressed genes. In clustering maps ([Fig. 1](#f1-mmr-16-02-1278){ref-type="fig"}), genes from different groups were clearly distinguished, illustrating that the microarray data represent the genomic transcripts well. Significantly enriched GO and KEGG pathways among blastocysts of the three groups are demonstrated in [Tables V](#tV-mmr-16-02-1278){ref-type="table"}--[VII](#tVII-mmr-16-02-1278){ref-type="table"}. The certain expression changes were confirmed by RT-qPCR. MAT2A, COMT, PER1, STK4 were analyzed by RT-qPCR in the IVM group and *in vivo* group ([Fig. 2](#f2-mmr-16-02-1278){ref-type="fig"}) MAT2A, COMT and STK4 were significantly differentially expressed in the RT-qPCR analysis and were upregulated in IVM group. CCNG1, IL4I1, MAT2A, FOXP3 were analyzed by RT-qPCR in IVM-anti group and IVM group ([Fig. 3](#f3-mmr-16-02-1278){ref-type="fig"}). MAT2A and CCNG1 were significantly differentially expressed. MAT2A were downregulated and CCNG1 were upregulated in IVM-anti group.

### Detailed analysis of associated GO and KEGG pathways

Further analysis to determine which of the functional categories assigned by GO and the KEGG pathways were overrepresented at the 95% confidence level with a minimum overlap set to two genes. GO analysis and KEGG pathway analysis were performed using the standard enrichment computation method. The results are presented in [Figs. 4](#f4-mmr-16-02-1278){ref-type="fig"}--[7](#f7-mmr-16-02-1278){ref-type="fig"}.

Discussion
==========

In the majority of superovulation cycles, a small portion of oocytes remains immature after human chorionic gonadotropin stimulation. These oocytes are routinely abandoned because clinical outcomes of these oocytes are flawed ([@b19-mmr-16-02-1278]). In order to make good use of these oocytes, melatonin was added to the IVM system. The aim of our study was to evaluate the effect of melatonin in maturation medium for human '*rescue* IVM'.

As an effective antioxidant, melatonin is known to be associated with regulation of various dynamic physiological functions, and also is present in human preovulatory follicular fluid and may be associated with reproduction. The beneficial effects of melatonin are concentration dependent. The current study demonstrated that 10^−5^ mol/l was the appropriate concentration of melatonin.

In a previous study, improved maturation and embryonic development were observed in IVM supplemented with 10^−5^ mol/l melatonin ([@b10-mmr-16-02-1278]), which is consistent with the results of the present study. In another study on bovine oocyte maturation *in vitro*, the most effective melatonin concentrations ranged from 10^−9^-10^−7^ M; however, as the concentration of melatonin increased from 10^−9^-10^−3^ M, the cleavage rate and the blastocyst rate declined dramatically ([@b20-mmr-16-02-1278]). This was not surprising as high concentrations of melatonin inhibit human leukemia cell division ([@b21-mmr-16-02-1278]).

Consistent with the findings of the current study, Takasaki *et al* reported that oral melatonin supplementation had a beneficial effect on fertilization and embryo quality ([@b8-mmr-16-02-1278]). In a prospective, longitudinal, cohort study, treatment with myo-inositol and melatonin improved ovarian stimulation protocols and pregnancy outcomes in infertile women with poor oocyte quality ([@b22-mmr-16-02-1278]). Batıoğlu *et al* ([@b23-mmr-16-02-1278]) demonstrated that melatonin was likely to improve oocyte and embryo quality in women undergoing IVF or ICSI ([@b23-mmr-16-02-1278]). Rodriguez-Osorio *et al* ([@b24-mmr-16-02-1278]) demonstrated that melatonin had a positive effect on porcine embryo cleavage rates and blastocyst cell numbers. Taken together, these data suggest that melatonin supplementation may have a beneficial effect on embryo quality. The melatonin in follicular fluid may be synthesized by the oocytes ([@b25-mmr-16-02-1278]) and used to protect them from oxidative stress or other environmental insults by reducing the oxidation of macromolecules ([@b26-mmr-16-02-1278]). The quality of the oocyte and the embryo are critical for ART. Poor oocyte or embryo quality is directly associated with low developmental potential of the embryo.

Regulation of gene expression has an important role in embryonic development. Transcripts accumulated throughout the human oocyte growth phase control development until a transcriptionally active embryonic genome is established at the 4- to 8-cell stage of embryo development ([@b27-mmr-16-02-1278]). To further clarify the mechanisms by which melatonin mediates its beneficial effects on the quality of embryo, whole gene expression of human blastocysts from *in vivo* matured blastocysts, and '*rescue* IVM' blastocysts with or without melatonin treatment were profiled. In addition, the most differentially expressed genes (MAT2A, COMT, PER1, CCNG1), but also the less differentially expressed genes (PER1, FOXP3 and IL4I1) were selected for RT-qPCR validation. These genes were selected out of the numerous differentially expressed genes as they are involved in the significantly enriched GO and pathways of blastocysts, which include methylation, cation channel sperm-associated protein 1, negative regulation of Wnt signaling pathway, p53 signaling pathway, L-amino-acid oxidase and regulation of neuron apoptotic process, which have an important role in regulating embryonic growth.

In vitro and in vivo
====================

The large-scale analysis of the transcriptome revealed significant differences in mRNA expression levels. Firstly, a number of the genes that were differentially expressed when comparing the IVM group and *in vivo* group (PQ loop repeat containing 2, PRA1 domain family member 2, solute carrier family 38 member 6, glutamate metabotropic receptor 7, COMT, MAT2A, spermidine synthase, metallothionein 1A, STK4 and others) were involved in organic anion transport, cysteine and methionine metabolism, methylation, regulation of apoptotic process, mineral absorption, steroid hormone biosynthesis, Wnt signaling pathway. These changes likely reflected differences in restructuring of the cells of the blastocyst during maturation between the *in vitro* and *in vivo* conditions. Many genes that were involved in stress response and metabolism also varied between *in vitro* and *in vivo* (glutamate-cysteine ligase modifier subunit, LDL receptor related protein 1, BCL2 like 11 and forkhead box O3) suggesting sub-optimal oxidative and nutritive conditions *in vitro* compared with *in vivo*.

Cysteine and methionine metabolism pathway genes were upregulated in the IVM group compared with the *vivo* group. Genes, such as MAT2A, involved in this process were upregulated. Cysteine and methionine metabolism is an epigenetic pathway associated with DNA methylation that has an important role in regulating embryonic growth and establishment/maintenance of genomic imprints ([@b28-mmr-16-02-1278]). DNA methylation differences between *in vitro*- and *in vivo*-conceived children were previously reported to be associated with ART procedures rather than infertility ([@b29-mmr-16-02-1278]). The potential for ARTs to adversely affect the epigenetic status of the developing embryo had been widely discussed; particularly its potential role in increasing the relative risk of imprinting defect syndromes, such as Beckwith-Wiedemann and Angelman syndr\`omes ([@b30-mmr-16-02-1278]). Incomplete methylation of maternal loci during oocyte development may have serious consequences during development and is of particular concern for IVM.

By contrast, Kuhtz *et al* ([@b31-mmr-16-02-1278]) demonstrated that human *in vitro* oocyte maturation was not associated with increased imprinting error rates at the KCNQ1 opposite strand/antisense transcript 1, small nuclear ribonucleoprotein polypeptide N, paternally expressed 3 and maternally expressed 3 genes ([@b31-mmr-16-02-1278]). Pliushch *et al* ([@b32-mmr-16-02-1278]) reported that *in vitro* maturation of oocytes was not associated with altered deoxyribonucleic acid methylation patterns in children from *in vitro* fertilization or intracytoplasmic sperm injection ([@b32-mmr-16-02-1278]).

The sample size of microarray analysis in the present study was relatively small. The MAT2A and COMT genes, which are associated with DNA methylation, were selected for RT-qPCR validation comparing expression in the IVM group and *in vivo* group; the expression of MAT2A and COMT were significantly different in these groups. However, whether IVM had an effect on epigenetics should be clarified in further research.

Melatonin treatment
===================

To the best of our knowledge, establishing a mature epigenetic status in the genome is part of the maturation process of the oocyte and is essential for embryo development following fertilization. Certain reports have suggested that melatonin may regulate the genome methylation status ([@b33-mmr-16-02-1278]--[@b36-mmr-16-02-1278]). Li *et al* ([@b6-mmr-16-02-1278]) reported that melatonin increased imprinted gene expressions of sirtuin 1, AKT serine/threonine kinase 2, and DNA polymerase γ 2. In the current study, MAT2A and COMT expression, which is involved in the pathway of cysteine and methionine metabolism, were significantly downregulated in the melatonin-treated group compared with no melatonin, suggesting that melatonin may regulate epigenetic status; this may be a factor that mediates the effect of melatonin on the quality of embryos. When comparing the expression between the IVM with melatonin treatment group and *in vivo* group, no differentially expressed genes involved in DNA methylation were detected. Thus, melatonin may correct DNA methylation changes caused by the '*rescue* IVM' procedure.

In the present study, the p53 signaling pathway was up regulated in the-melatonin treated group compared with no melatonin treatment. Differentially expressed genes cyclin E1, CCNG1, damage specific DNA binding protein 2 and protein phosphatase, Mg^2+^/Mn^2+^ dependent 1D were also up regulated. p53 is known as the guardian of the genome and has a major role in DNA repair and apoptosis ([@b36-mmr-16-02-1278]). The cells undergo apoptosis in response to unrepaired DNA via p53-mediated activation ([@b37-mmr-16-02-1278]). The p53 pathway is induced by a number of stress signals, including oxidative stress, DNA damage and activated oncogenes. Over the past three decades researchers have identified p53 as a multi-functional transcription factor. p53 affects highly diverse cellular processes, and is one of the most important and extensively studied tumor suppressors ([@b38-mmr-16-02-1278]). p53-regulated gene functions communicate with adjacent cells, repair damaged DNA, and set up positive and negative feedback loops that enhance or attenuate the functions of the p53 protein, integrating these stress responses with other signal transduction pathways ([@b39-mmr-16-02-1278]). It was previously reported that apoptosis is suppressed by p53 in post-mitotic spermatogenic cells to avoid excess death of spermatocytes to guarantee the robustness of spermatogenesis ([@b40-mmr-16-02-1278]). Therefore, upregulated p53 signaling pathway may be another mechanism of action by melatonin.

Blastocyst formation is a crucial stage in early embryo development. Genes regulate the development and differentiation of the inner cell mass and trophectoderm of the embryo, which controls the transition from the undifferentiation to differentiation stage. The results of the current study also demonstrated that negative regulation of canonical Wnt signaling pathway was downregulated in the IVM group without melatonin treatment compared with the *in vivo* group \[differentially expressed genes were G3BP stress granule assembly factor 1, MAD2L2, nephrocystin 4, sonic hedgehog, STK4, receptor for activated C kinase 1\], but no difference in the Wnt signaling pathway were detected between the IVM with melatonin treatment and the *in vivo* group. Wnt signaling was first identified for its role in carcinogenesis, but had since been recognized for its function in embryonic development range from cell fate determination, cell cycle, body axis patterning to cell fate specification, cell proliferation, and cell migration ([@b41-mmr-16-02-1278]). Wnts were highly evolutionarily conserved in animals ([@b42-mmr-16-02-1278]). Melatonin may also act via effects on Wnt signaling.

NET working
===========

The mechanisms of network of interaction between various signaling pathways had been investigated. Several authors have reported that apoptotic activation of p53 is mediated by activation of extracellular signal-regulated kinase, p38 mitogen-activated protein kinase and c-Jun N-terminal kinase pathways ([@b43-mmr-16-02-1278]). Other studies have determined the effects of microRNAs (miRNAs). miRNAs are a group of noncoding regulatory RNAs known to influence the stability and translational efficiency of target mRNAs. Kim *et al* ([@b44-mmr-16-02-1278]) reported that p53 and miRNA-34 re suppressors of the canonical Wnt signaling pathway; their data provided insight into the mechanisms by which a p53-miRNA-34 network restrained canonical Wnt signaling cascades in developing organisms and human cancer. In another study, miRNAs were reported to be associated with human embryo implantation defects ([@b45-mmr-16-02-1278]). Melatonin was demonstrated to exert its biological functions by modulation of miRNA expression in human breast cancer cells ([@b46-mmr-16-02-1278]). Thus, melatonin may affect miRNAs, which may regulate the network of interaction between the p53 and Wnt signaling pathways in *in vitro* maturation of oocytes.

In summary, gene expression profiling using whole human genome arrays and subsequent data analysis provided a molecular basis for the relative higher quality of IVM blastocysts treated with melatonin compared with those without melatonin treatment. Certain genes identified in the current study, including MAT2A, COMT, CCNG1, and STK4, may be useful as the biomarkers of IVM safety. The IVM procedure may potentially affect gametes and embryos by causing disorders of DNA methylation patterns and the canonical Wnt signaling pathway. Exogenous melatonin treatment positively influenced the quality of blastocysts, and regulated the p53 signaling pathway and genes associated with DNA methylation during '*rescue* IVM'. However, the current study was limited due to the suboptimal source of the oocytes and limited sample size. This study reflects what is generally referred to as '*rescue* IVM' and was not a true reflection of clinical IVM techniques. Therefore, as a promising IVM supplement, the role of melatonin requires further investigation.

The study has been supported by the Cultivating Youth Training Program (2015KJ03) in The First Affiliated Hospital of Anhui Medical University.
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###### 

Clinical characteristics among groups treated with varying melatonin concentrations.

  Melatonin treatment group (mol/l)   Age (years)   Body mass index   Total Gn dose (IU)   Gn using days
  ----------------------------------- ------------- ----------------- -------------------- ---------------
  0                                   27.0±2.62     20.42±1.52        1,730±400.10         11.2±1.69
  10^−5^                              27.3±3.62     21.85±3.33        1,862±541.98         12.1±2.33
  10^−7^                              27.5±3.59     22.41±2.88        2,104±533.11         12.4±2.67
  10^−9^                              28.4±3.03     21.16±2.71        1,982±453.28         10.9±1.37
  10^−11^                             27.6±3.37     22.99±2.31        2,280±420.49         12.8±2.65

n=40 per group. Gn, gonadotropin.

###### 

Primer sequences.

  Gene    Bidirectional primer sequences    Size (bp)
  ------- --------------------------------- -----------
  GAPDH   F: 5′GGGAAACTGTGGCGTGAT3′         299
          R: 5′GAGTGGGTGTCGCTGTTGA3′        
  MAT2A   F: 5′TGGAGACCAGGGCTTAATGTTTG3′    114
          R: 5′TTACGGCGTAGTTCTGCCAGTTT3′    
  PER1    F: 5′TACCAGCCATTCCGCCTAAC3′       196
          R: 5′ CAGCCCTTTCATCCACATCC3′      
  STK4    F: 5′TGAAACTGAAACGCCAGGAAT3′      120
          R: 5′TGCCCATCTCATCACCCACT3′       
  CCNG1   F: 5′ATGACAAGCCTGAGAAGGTAAA3′     142
          R: 5′TGTGGGAAGACTGATAGTTGATAG3′   
  IL4I1   F: 5′ CCCTCAAAGACCTCAAGGCACT3′    168
          R: 5′ CCTCGGCGAAGCTGAGATAGA3′     
  COMT    F: 5′GCTGAAGAAGAAGTATGATGTGGA3′   220
          R: 5′CAGGAACGATTGGTAGTGTGTG3′     
  FOXP3   F: 5′AGGAAAGGAGGATGGACGAA3′       124
          R: 5′GGCAGGCAAGACAGTGGAA3′        

All primers had a Tm of 60°C. F, forward; R, reverse; MAT2A, methionine adenosyltransferase 2A; PER1, period circadian clock 1; STK4, serine/threonine kinase 4; CCNG1, cyclin G1; IL4I1, interleukin 4 induced 1; COMT, catechol-O-methyltransferase; FOXP3, forkhead box P3.

###### 

Embryo development in groups of varying MT concentrations.

  MT treatment group (mol/l)   Total no. of oocytes (GV/MI)   Total no. of matured oocytes maturation rate %)   Total no. of fertilized oocytes (fertilization rate %)   Total no. of cleaved oocytes (cleavage rate %)   Total ho. of blastocysts (Blastocyst rate %)   Total ho. of high quality blastocyst (high quality blastocyst rate %)
  ---------------------------- ------------------------------ ------------------------------------------------- -------------------------------------------------------- ------------------------------------------------ ---------------------------------------------- -----------------------------------------------------------------------
  0                            135 (70/65)                    101 (76.1±2.2)                                      80 (84.8±1.9)                                          73 (86.4±2.6)                                    14 (23.3±3.5)                                    2 (11.1±3.3)^[a](#tfn4-mmr-16-02-1278){ref-type="table-fn"}^
  10^−5^                       159 (66/93)                    112 (78.9±2.9)                                    101 (94.0±1.5)                                           93 (97.9±1.4)                                    26 (29.1±3.6)                                  14 (54.4±4.7)^[b](#tfn5-mmr-16-02-1278){ref-type="table-fn"}^
  10^−7^                       103 (48/55)                      79 (81.1±2.5)                                     71 (90.7±2.2)                                          64 (82.4±3.6)                                    11 (14.0±2.4)                                    3 (27.3±4.6)^[a](#tfn4-mmr-16-02-1278){ref-type="table-fn"}^
  10^−9^                       117 (64/53)                      93 (79.7±3.2)                                     82 (89.7±2.1)                                          78 (92.1±2.1)                                    14 (16.3±2.8)                                    3 (21.1±4.2)^[a](#tfn4-mmr-16-02-1278){ref-type="table-fn"}^
  10^−11^                      120 (66/54)                      82 (69.6±3.7)                                     68 (85.4±2.4)                                          66 (94.2±2.2)                                    11 (14.6±2.3)                                    2 (15.4±3.2)^[a](#tfn4-mmr-16-02-1278){ref-type="table-fn"}^

Percentage data are presented as the mean ± standard error. Values marked with different letters are statistically different to each other (P\<0.05).

P\>0.05 between the 0, 10^−7^, 10^−9^ and 10^−11^ mol/l groups

P\<0.05 10^−5^ mol/l vs. all other groups. Maturation rate, no. of matured oocytes/total no. of oocytes; fertilization rate, no. of fertilized oocytes/no. of matured oocytes; cleavage rate, no. of cleaved oocytes/no. of fertilized oocytes; blastocyst rate, no. of blastocysts/no. of cleaved oocytes; high quality blastocyst rate, no. of high quality blastocysts/no. of blastocysts.

###### 

Differentially expressed genes in the IVM, IVM-anti and *in vivo* groups.

  A, IVM group vs. *in vivo* group                                                                       
  --------------------------------------- ------------------- ---------------------- --------- --------- -------------------------------------------
  MAT2A                                   NM_005911           Up                     0.99997   0.03405   S-adenosylmethionine synthetase
  COMT                                    NM_000754           Up                     0.70388   0.00733   Catechol-O-methyltransferase
  ZNF335                                  NM_022095           Up                     0.96627   0.01522   Methylation
  PER1                                    NM_002616           Up                     0.99997   0.01977   Cation channel sperm-associated protein 1
  FOXO3                                   NM_001455           Up                     0.99997   0.02969   Transcription factors
  STK4                                    NM_006282           Down                   0.97854   0.01614   Phosphorylating
  NPHP4                                   NM_015102           Down                   0.99997   0.03147   Chromosome and associated proteins
                                                                                                         
  B, IVM-anti group vs. IVM group                                                                        
                                                                                                         
  Gene symbol                             GenBank accession   Regulation direction   FDR       P-value   Biological processes
  CCNE1                                   NM_001238           Up                     0.47303   0.01166   G1/S-specific cyclin E1
  CCNG1                                   NM_004060           Up                     0.30861   0.00296   Cyclin G1
  MAT2A                                   NM_005911           Down                   0.58916   0.03081   S-adenosylmethionine synthetase
  IL4I1                                   NM_152899           Down                   0.60742   0.04633   L-amino-acid oxidase
  ATP8                                    AK128101            Down                   0.44454   0.00934   Mitochondrial biogenesis
                                                                                                         
  C, IVM-anti group vs. *in vivo* group                                                                  
                                                                                                         
  Gene symbol                             GenBank accession   Regulation direction   FDR       P-value   Biological processes
  DUSP4                                   NM_001394           Up                     0.10966   0.00199   Dual specificity MAP kinase phosphatase
  LRG1                                    NM_052972           Up                     0.12045   0.00249   DNA repair and recombination proteins
  ATP5J                                   NM_001003703        Down                   0.36829   0.03604   ATP synthase
  COX6B                                   NM_144613           Down                   0.13547   0.00334   Cytochrome c oxidase subunit 6b

FDR was estimated to evaluate the probability of false positive associations. FDR, false discovery rate; IVM, in vitro maturation; MAT2A, methionine adenosyltransferase 2A; COMT, catechol-O-methyltransferase; ZNF335, zinc finger protein 335; PER1, period circadian clock 1; FOXO3, forkhead box O3; STK4, serine/threonine kinase 4; NPHP4, nephrocystin 4; CCNE1, cyclin E1; CCNG1, cyclin G1; IL4I1, interleukin 4 induced 1; ATP8, ATP synthase F0 subunit 8; DUSP4, dual specificity phosphatase 4; LRG1, leucine rich α-2-glycoprotein 1; ATP5 J, ATP synthase H^+^ transporting, mitochondrial Fo complex subunit F6; COX6B, cytochrome c oxidase subunit 6B1.

###### 

Significantly enriched Gene Ontology and pathways of blastocysts between in IVM group vs. *in vivo* group.

  GO/Pathway ID   Regulation direction   Count   Description                                              Gene symbols
  --------------- ---------------------- ------- -------------------------------------------------------- ---------------------------------------------------------------------
  GO:0015711      Up                     9       Organic anion transport                                  PQLC2, PRAF2, SLC38A6, GRM7, SLC26A6, ABCB11, SLC15A4, MFSD10, SCP2
  GO:0000096      Up                     3       Sulfur amino acid metabolic process                      GCLM, COMT, MAT2A
  GO:0034754      Up                     4       Cellular hormone metabolic process                       SCP2, HSD17B3, DHRS9, COMT
  GO:0032259      Up                     5       Methylation                                              ZNF335, CMTR2, COMT, MAT2A, PRDM15
  GO:0043523      Up                     4       Regulation of neuron apoptotic process                   GCLM, LRP1, BCL2L11, FOXO3
  hsa00270        Up                     2       Cysteine and methionine metabolism                       MAT2A, SRM
  hsa00480        Up                     2       Glutathione metabolism                                   GCLM, SRM
  hsa04978        Up                     2       Mineral absorption                                       MT1A, SLC26A6
  hsa00140        Up                     2       Steroid hormone biosynthesis                             COMT, HSD17B3
  GO:0030178      Down                   6       Negative regulation of Wnt signaling pathway             G3BP1, MAD2L2, NPHP4, SHH, STK4, GNB2L1
  GO:0090090      Down                   5       Negative regulation of canonical Wnt signaling pathway   G3BP1, MAD2L2, NPHP4, SHH, STK4
  GO:0035329      Down                   3       Hippo signaling                                          NPHP4, STK4, TEAD3
  GO:0021510      Down                   5       Spinal cord development                                  SHH, MDGA2, MDGA1, EVX1, NEUROG3

Pathway IDs were produced from KEGG analysis. Count indicates the number of differentially expressed genes associated with the listed GO/pathway ID. IVM, in vitro maturation; GO, gene ontology.

###### 

Significantly enriched Gene Ontology and pathways of blastocysts in the IVM-anti group vs. *in vivo* group.

  GO/pathway ID   Regulation direction   Count   Description                                                                      Gene symbol
  --------------- ---------------------- ------- -------------------------------------------------------------------------------- ----------------------------------------------------------------
  GO:0010563      Up                     29      Negative regulation of phosphorus metabolic process                              DUSP4, CAV1, MEN1, NTRK3, DNAJC10, PID1, MICAL1, ZBED3, PPAP2B
  GO:0030511      Up                     29      Positive regulation of transforming growth factor β receptor signaling pathway   LRG1, FLCN, MEN1, THBS1, MYOCD
  hsa04115        Up                       7     p53 signaling pathway                                                            CCNE1, CCNG1, DDB2, PPM1D, SHISA5, STEAP3, THBS1
  hsa00190        Down                     8     Oxidative phosphorylation                                                        ATP5J, ATP8, COX6B2, ND1, ND2, ND3, NDUFA6, SDHC
  hsa05012        Down                     2     Parkinson\'s disease                                                             ATP5J, ATP8, COX6B2, ND1, ND2, ND3, NDUFA6, SDHC, UBA7

Pathway IDs were produced from KEGG analysis. Count indicates the number of differentially expressed genes associated with the listed GO/pathway ID. IVM, in vitro maturation; GO, gene ontology.

###### 

Significantly enriched Gene Ontology and pathways of blastocysts in IVM-anti group vs. IVM group.

  GO/pathway ID   Regulation   Count   Description                          Gene symbol
  --------------- ------------ ------- ------------------------------------ --------------------------------------------------------
  GO:0010942      Up           20      Positive regulation of cell death    ADIPOQ, BCL2L11, VAV3, TRIM35, NCSTN, NOTCH2, ADAMTSL4
  GO:0043549      Up           30      Regulation of kinase activity        CDK5R2, CCNE1, CCNG1, GNAI2, MOS, NTRK3, THBS1, DUSP4
  hsa04115        Up             5     p53 signaling pathway                CCNE1, CCNG1, CD82, STEAP3, THBS1
  hsa00270        Down           2     Cysteine and methionine metabolism   IL4I1, MAT2A
  hsa05016        Down           5     Huntington\'s disease                ATP8, NDUFV3, POLR2G, POLR2J, SDHC

Pathway IDs were produced from KEGG analysis. Count indicates the number of differentially expressed genes associated with the listed GO/pathway ID. IVM, in vitro maturation; GO, gene ontology.
